Boston Scientific names Fitzgerald COO and Boston Scientific stock costs EUR 38.34
Published on 10/12/2026 at 12:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey points in brief
- Boston Scientific appointed Joseph M. Fitzgerald as chief operating officer effective January 1, 2027, alongside a three-segment structure.
- The company generated USD 5.44 billion in revenue in the second quarter of 2026, up 7.50 percent year over year.
- Boston Scientific stock was trading at EUR 38.34 at Lang & Schwarz on October 12, 2026 at 12:25 p.m. CEST.
- Third-quarter results and an updated outlook are scheduled for October 28, 2026.
Boston Scientific stock was trading at EUR 38.34 at Lang & Schwarz on October 12, 2026 at 12:25 p.m. CEST. On October 7, Boston Scientific appointed Joseph M. Fitzgerald as executive vice president and chief operating officer effective January 1, 2027, according to PR Newswire.
Three-segment structure starts January 1
Fitzgerald will oversee Boston Scientific global operations, business units and regions. The company will establish three reportable segments on January 1, 2027: Interventional Therapies, Rhythm Solutions and MedSurg, a structure management said is designed to speed decisions and improve investment allocation.
The appointment gives the management change an operating dimension. Fitzgerald currently leads the Cardiovascular group, while the new structure assigns segment responsibilities across cardiovascular, rhythm, endoscopy, urology and neuromodulation activities.
What does the outlook reset involve?
Boston Scientific generated USD 5.44 billion in revenue in the second quarter of 2026, representing 7.50 percent reported growth from the second quarter of 2025. Adjusted earnings per share reached USD 0.86, up 15.00 percent year over year, according to the company earnings-call transcript published by Yahoo Finance.
Management guided to third-quarter 2026 organic revenue growth of 3.00 percent to 5.00 percent and adjusted earnings per share of USD 0.80 to USD 0.82. The same call described weaker conditions in WATCHMAN and electrophysiology, while interventional cardiology, neuromodulation and interventional oncology delivered double-digit growth in the first half of 2026.
Three dated steps frame the stock
On January 15, 2026, Boston Scientific announced an agreement to acquire Penumbra, with the transaction expected to close in the second half of 2026. On July 29, 2026, second-quarter revenue reached USD 5.44 billion and adjusted earnings per share reached USD 0.86. On October 7, 2026, Fitzgerald was named chief operating officer for January 1, 2027, and the three-segment structure was announced.
Next dates for Boston Scientific
Boston Scientific is scheduled to report third-quarter 2026 results on October 28, 2026, with an updated outlook expected alongside the release. The new operating structure is scheduled to take effect on January 1, 2027.
Stock price and market context
The latest euro quotation places Boston Scientific stock at EUR 38.34 at Lang & Schwarz on October 12, 2026 at 12:25 p.m. CEST. The primary listing is on the NYSE, where the stock was last quoted at USD 42.73 on October 9, 2026; the same market data showed a 52-week range of USD 41.39 to USD 105.65 and market capitalization of USD 63.5 billion.
The further course of trading is shown by the continuously updated real-time quote of Boston Scientific stock.
Boston Scientific stock facts
- Company: Boston Scientific Corporation
- ISIN: US1011371077
- Ticker: BSX
- Primary exchange: NYSE
- Price Lang & Schwarz as of October 12, 2026, 12:25 p.m. CEST: EUR 38.34
- Market capitalization: USD 63.5 billion as of October 9, 2026
- 52-week range: USD 41.39-105.65 as of October 9, 2026
- Sector / Industry: Healthcare / Medical Devices
- Index membership: S&P 500
- Next earnings date: October 28, 2026
Market context: Market report S&P 500.
